Vyvgart Hytrulo (Efgartigimod Alfa And Hyaluronidase Drug Interactions
Vyvgart Hytrulo (Efgartigimod Alfa And Hyaluronidase (Human Recombinant)) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Vyvgart Hytrulo. Always confirm against the full prescribing information.
100 interactions
Adenovirus type 7 vaccine live
The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Adenovirus type 7 vaccine live.
Level 1 evidence
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Efgartigimod alfa.
Level 2 evidence
Anthrax vaccine
The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Anthrax vaccine.
Level 1 evidence
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Efgartigimod alfa.
Level 2 evidence
Bacillus calmette-guerin substrain tice live antigen
The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Bacillus calmette-guerin substrain tice live antigen.
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Efgartigimod alfa.
Level 2 evidence
Chikungunya vaccine (live, attenuated)
The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Chikungunya vaccine (live, attenuated).
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efgartigimod alfa.
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efgartigimod alfa.
Level 2 evidence
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Efgartigimod alfa.
Level 1 evidence
Acetylsalicylic acid
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Acetylsalicylic acid.
Level 1 evidence
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Efgartigimod alfa.
Level 2 evidence
Enter your NPI to unlock 64 major interactions for Vyvgart Hytrulo
Vyvgart Hytrulo (Efgartigimod Alfa And Hyaluronidase (Human Recombinant)) has 363 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Vyvgart Hytrulo (Efgartigimod Alfa And Hyaluronidase (Human Recombinant)) has 234 major, 49 moderate, and 80 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Vyvgart Hytrulo. Always confirm against the full prescribing information.